aibioGeron faces Rytelo securities class action and four derivative suits
Tickers GERN
Geron is a defendant in a consolidated securities class action over statements about RYTELO, and four derivative suits repeat the claims. The class action was dismissed without prejudice on March 30, 2026, and a second amended complaint is now under a motion to dismiss.
Key facts
- Company
- Geron Corporation (NASDAQ: GERN)
- News type
- Legal
- Primary source
- Geron Corporation 10-Q for the quarter ended June 30, 2026 (SEC EDGAR)
Geron Corporation (Nasdaq: GERN) is a defendant in a consolidated securities class action in the U.S. District Court for the Northern District of California and in several derivative suits, according to its 10-Q filed August 5, 2026. The class action named Geron and certain of its current and former officers. The derivative suits name certain current and former directors and officers. The 10-Q does not list the individuals.
The class action began as two suits, Dabestani v. Geron Corporation, et al., No. 3:25-cv-02507, and Potvin v. Geron Corporation, et al., No. 3:25-cv-02563, filed on March 13 and March 14, 2025. The derivative captions lead with John A. Scarlett, M.D., Geron's former chief executive officer, and Dawn C. Bir, a director who became interim president and chief executive officer on March 10, 2025.
The class action
Both class action complaints allege violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. They allege false and misleading statements about the commercial potential of RYTELO. The plaintiffs say Geron overstated that potential and concealed adverse facts, including low awareness among healthcare providers, the burden of monitoring requirements, seasonality and existing competition. They also say the stock fell after Geron said on a February 26, 2025 earnings call that it had seen flat revenue trends over the prior few months. The 10-Q gives no class period.
The derivative suits
Four derivative suits repeat the allegations: Bishop v. Scarlett, et al., No. 3:25-cv-03356, Lerner v. Scarlett, et al., No. 3:25-cv-03401, and Willis v. Scarlett, et al., No. 3:25-cv-03396, filed April 15 and 16, 2025, and Jae Hyung v. Bir, et al., No. 3:25-cv-08575, filed October 7, 2025. The plaintiffs say the directors and officers breached their fiduciary duties and violated federal securities laws by making the same statements. They seek damages and costs, and the Bishop and Willis plaintiffs also seek punitive damages.
Geron's proxy statement filed April 8, 2025 shows who held the main roles when the suits began. Scarlett served as chair, president and chief executive officer until March 10, 2025. The proxy lists seven directors: Bir, Elizabeth G. O'Farrell, Gaurav Aggarwal, V. Bryan Lawlis, Susan Molineaux, John F. McDonald and Robert J. Spiegel. The filings do not say which of them, beyond the caption names, are defendants.
Where it stands
The court consolidated the class actions on May 29, 2025 as In re Geron Corporation Securities Litigation and appointed lead plaintiffs. They filed a consolidated amended complaint on August 8, 2025, and Geron moved to dismiss on October 7, 2025. After a March 19, 2026 hearing, the court granted the motion without prejudice on March 30, 2026.
The lead plaintiffs filed a second amended complaint on April 13, 2026. Geron moved to dismiss it on May 18, the plaintiffs opposed on June 22, and Geron replied on July 10. The 10-Q gives no hearing date or ruling.
The court consolidated the first three derivative suits on May 16, 2025 as In re Geron Corporation Derivative Litigation, and stayed them on June 17, 2025 until the motion to dismiss in the class action is decided. The fourth plaintiff made a demand on the board on August 29, 2025, and the board said on September 19, 2025 that it would defer a decision.
What the company says
Geron says it cannot reasonably estimate possible losses. It warns that the expenses could be material if it does not prevail in the defense of these suits, and could be material even if it does. It has indemnification agreements with each director and officer and buys standard insurance for claims against them.
The suits center on RYTELO, Geron's commercial product, and they land while the company still loses money. Geron reported a net loss of $83.5 million for 2025 and used $111.0 million in operations that year. Its net loss was $16,680 thousand for the second quarter of 2026, and cash, cash equivalents and restricted cash fell to $64,531 thousand at June 30, 2026. One tranche of its term loans becomes available only if RYTELO reaches a trailing twelve-month revenue milestone.